Welcome to our dedicated page for ZEAL news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on ZEAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEAL's position in the market.
Zealand Pharma will host a conference call on August 12, 2021, at 4 pm CET (10 am ET) to discuss its Q2 2021 results. Presenters include CEO Emmanuel Dulac, CFO Matt Dallas, and CMO Adam Steensberg. The event will feature a Q&A session and will be conducted in English. Dial-in numbers for various regions, including the US, UK, and Denmark, are provided. A live audio webcast and slide presentation will be accessible on Zealand's investor website. Participants should register 30 minutes prior. A recording will be available post-call.
Zealand Pharma A/S has completed its share repurchase program, acquiring up to DKK 32,070,896 worth of shares, totaling 154,187 shares. The program, managed by Danske Bank A/S, was initiated on June 29, 2021, to support incentive programs. Following the transactions, Zealand holds a total of 218,410 shares as treasury shares, representing 0.5% of its total share capital of DKK 43,541,838. The average repurchase price per share was DKK 185.48, with a total value of DKK 28,597,426.
Zealand Pharma A/S announced a share repurchase program initiated on June 29, 2021, aimed at acquiring up to DKK 32,070,896 in Danish common stock for incentive programs. Danske Bank A/S manages the program independently. As of the latest transactions, Zealand has repurchased a total of 134,065 shares, valued at DKK 24,886,411. This represents 0.46% of the total share capital of Zealand, which stands at DKK 43,541,838. The program is set to conclude by July 29, 2021.
Zealand Pharma A/S announced on July 13, 2021, the continuation of its share repurchase program initiated on June 29, with a cap of DKK 32,070,896 to acquire up to 154,187 Danish common shares. The program, managed by Danske Bank A/S, is set to complete by July 29, 2021. Transactions since July 6, 2021, included the purchase of 36,000 shares at an average price of DKK 191.13, totaling DKK 6,861,210. Zealand currently holds 149,223 treasury shares, equating to 0.34% of its total share capital of DKK 43,541,838.
On June 29, 2021, Zealand Pharma A/S initiated a share repurchase program, planning to acquire up to DKK 32,070,896 worth of shares for incentive programs. Danske Bank A/S is managing the program, expected to complete by July 29, 2021, acquiring up to 154,187 shares. As of July 5, 2021, Zealand repurchased 49,000 shares at an average price of DKK 185.07, totaling DKK 9,068,340. With these transactions, Zealand holds 113,223 treasury shares, representing 0.0026% of its total share capital.
Zealand Pharma A/S announced the total number of shares and voting rights on June 30, 2021, following an increase in share capital due to employee warrants exercises. As of this date, Zealand maintains 43,541,838 shares and 43,541,838 voting rights, reflecting no changes in share capital since the previous reporting. Zealand Pharma focuses on peptide-based medicines, having two products on the market and several in clinical development. The company continues to engage in collaborations to expand the reach of its medicines.
Zealand Pharma announced it will present three posters on glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA) from June 30 to July 2, 2021, in Auckland, New Zealand. The data focus on treating Short Bowel Syndrome (SBS) and suggest no need for dosage adjustments in patients with renal impairment. The company emphasizes the potential of glepaglutide as a long-acting GLP-2 analog, with significant implications for SBS management.
Zealand Pharma A/S announced a share buy-back program beginning June 29, 2021, in accordance with the Safe Harbour Regulation. The program has a maximum budget of DKK 32,070,896 and will repurchase up to 154,187 shares. Danske Bank A/S will manage the repurchases independently. The buy-back will adhere to trading limits and pricing constraints. Currently, Zealand holds 64,223 treasury shares, representing 0.01% of total share capital. The program aims to enhance employee incentive structures and is set to conclude by July 29, 2021.
Zealand Pharma has announced the U.S. commercial availability of ZEGALOGUE® (dasiglucagon) injection for treating severe hypoglycemia in patients with diabetes aged 6 and older. ZEGALOGUE is now available in both an auto-injector and prefilled syringe format. The company also introduced the ConnectedCare patient support program to provide educational and affordability resources. The FDA approved ZEGALOGUE on March 22, 2021. The treatment aims to enhance safety for patients with diabetes, addressing the critical nature of severe hypoglycemic events.
Zealand Pharma (Nasdaq: ZEAL) announces participation in the LifeSci Nordic Biotech Summit on June 29, 2021. Senior management will present virtually at 1:30 p.m. ET / 7:30 p.m. CET. A live webcast will be accessible on the Company's website under the 'Events & Presentations' section and will be archived post-event. Zealand specializes in developing innovative peptide-based medicines, having advanced over 10 drug candidates into clinical development, with two currently on the market.
